Home > BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment

BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACC 2019
Trial
PARADIGM-HF
Despite an initial increase in B-Type Natriuretic Peptide (BNP) after initiation of treatment with sacubitril/valsartan in approximately 60% of patients, it has been assessed that BNP remains a reliable prognostic marker before and during treatment with sacubitril/valsartan [1]. Natriuretic peptides are substrates of neprilysin, and BNP concentrations rise with neprilysin inhibition. This has led to research into the clinical validity of measuring BNP in sacubitril/valsartan-treated patients and the use of N-terminal pro-BNP (NT-proBNP) being preferred and recommended. Vaduganathan et al. aimed to determine the prognostic performance of BNP before and during treatment with sacubitril/valsartan. Data was analysed from the randomised, double-blind, parallel group, active-controlled PARADIGM-HF trial, which compared the long-term efficacy and safety of sacubitril/valsartan with enalapril in patients with HFrEF [1,2]. BNP measurements were analysed in a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on